Author Profile

FDA Greenlights Phase 3 Trial for Lexicon Non-Opioid Pain Pill
Pilavapadin uses the novel target of neurotransmitters involved in pain signaling rather than opiate pathways. read more
Corxel Raises $287M to Advance Oral GLP-1
Funds will enable the company to initiate phase 3 trials of CX11 in the U.S. and progress with its programs for ischemic stroke and hypertension. read more
Uncorking 2026: Industry leaders raise a glass to the future of OSD
As the industry looks toward 2026, oral solid dosage forms remain firmly at the center of pharmaceutical and nutraceutical innovation — but the forces shaping the market are becoming more complex and interconnected. read more
Takeda Cuts U.S. Jobs as Depression Drug Patent Loss Looms
The cuts are the latest in a round of layoffs as the company reprioritizes its resources and launches an “efficiency program.” read more
Corvus Advances Eczema Pill into Phase 2 Trial
Data from phase 1 show efficacy in patients who are resistant to dupilumab and JAK inhibitors. read more
Nxera Tees Up Approval of Insomnia Pill in South Korea
The company plans to submit a marketing authorization application for daridorexant in South Korea in the first quarter of 2026. read more
Melatonin Supplements Market Projected to Reach $13.1B Amid Surging Global Demand for Natural Sleep Aids
The market will reach $13.1 billion by 2035, fueled by shifting consumer behavior toward preventive health care and non-prescription sleep aids. read more
FDA Delays Review of Travere Drug in Rare Kidney Disorder
The FDA has determined that Travere needs to further characterize the clinical benefit of the oral, non-immunosuppressive therapy to gain approval. read more
Tablet Delamination and Capping: Developing a Game Plan
Tablet delamination and capping are the most common tablet defects, causing costly production disruptions and lost batches. read more
Walmart Launches Digital Health Hub
With many Americans struggling to afford health care, Walmart is taking action. read more
FDA Grants Orphan Drug Status to Novita Fascin Inhibitor in Pancreatic Cancer
NP-G2-044 has shown efficacy in blocking metastasis and, combined with immune checkpoint inhibitors, is effective at reinvigorating anti-tumor responses. read more
Lilly, Nvidia Launch AI Co-Innovation Lab
The first-of-its-kind co-innovation lab will focus on applying AI to tackle some of the most enduring challenges in drug discovery. read more
Lilly Buys Ventyx Bio to Advance Oral Immunology Drugs
Lilly will pick up clinical stage NLRP3 inhibitors in an all-cash $1.2 billion deal. read more
Chasing the North American Dream
Just as traveling salesmen once had to balance opportunity, risk and proximity to their customers, today’s pharmaceutical suppliers face similar pressures as they pursue the dream of the world’s largest pharma market. read more
Novo Launches Wegovy Pill in the U.S.
The oral medication was approved in December based on phase 3 trial results that showed an average weight loss of 17%. read more
Vanda Gets First New Motion Sickness Drug Approval in Decades
Three clinical trials on patients with histories of motion sickness showed that the treatment significantly reduced vomiting compared with a placebo. read more
Corcept Hit with CRL for Hypercortisolism Drug
Although the drug met its primary endpoint in a clinical trial, the FDA wants additional proof of effectiveness. read more
FDA Grants Priority Review to Axsome’s sNDA for Alzheimer’s Disease Agitation Drug
The agency has set a PDUFA target action date of April 30, 2026 for the oral NMDA receptor antagonist, sigma-1 agonist, and aminoketone CYP2D6 inhibitor. read more
Agios Expands Oral PK Activator Nod to Thalassemia
The new nod makes Aqvesme the only FDA-approved drug for anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia. read more
Biohaven Drug Fails in Major Depressive Disorder
BHV-7000 also fell short in a phase 3 bipolar mania trial back in March. read more

January/February 2026

2026 Annual Buyer’s Guide
View Issue

Subscribe to Magazine

Get started here for your complimentary print or digital subscription

Get started here for your complimentary print or digital subscription
Sign up Now »

Keep up with our latest articles, news and events. Plus, get special offers and more delivered to your inbox!